Aura Minerals (AUGO) began trading on the Nasdaq on Wed 16 July 25

Aura Minerals Inc. is a Canadian multi-national mining company that owns and operates gold and copper mines in Honduras, Brazil and Mexico. 

The company is headquartered in the British Virgin Islands, operated from its corporate office in Florida and has its stocks traded on the Toronto Stock Exchange and BDR on the B3.

• Founded: 1946
• Headquarters: Coral Gables, Florida
• Website: auraminerals.com
• Employees: 1,337
• CEO: Rodrigo Barbosa

 Ticker: AUGO

Aura Minerals priced 8.10 mln share IPO at $24.25 per share; 

Stock is already listed on Toronto Stock Exchange and Brazilian Stock Exchange and will now trade on the Nasdaq Global Select Market

 

  

BofA Securities and Goldman Sachs & Co. LLC are acting as Global Coordinators, BTG Pactual and Ita BBA are acting as Joint Bookrunners and Bradesco BBI, National Bank of Canada Financial Markets, RBC Capital Markets and Scotiabank are acting as Co-Managers of the offering.

===CVRx, Inc. (CVRX) reports Positive news on outpatient payment for Barostim

 

• Co announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026.
• This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.

==Core Scientific (CORZ) to be acquired by CoreWeave (CRWV)

 

CoreWeave to acquire Core Scientific (CORZ) in an all-stock transaction implying a total equity value of $9 bln, expected to close in the fourth quarter of 2025 

• Under the terms of the merger agreement, Core Scientific (CORZ) stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio.
• Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability.
• Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint1 with an incremental 1 GW+ of potential gross power available for expansion.
• As of July 3, 2025, the agreed-upon exchange ratio implies a total equity value of approximately $9.0 billion.
• This is calculated on a fully diluted basis and based on CoreWeave's 5-day VWAP. This represents a $20.40 per share value based on the closing price of CoreWeave Class A common stock as of July 3, 2025, and a premium of approximately 66% to the unaffected Core Scientific closing share price of $12.30 on June 25, 2025.
• The final value will be determined at the time of transaction close.
• Upon close, CoreWeave expects Core Scientific's stockholders' ownership of the combined company will be less than 10%.